Cannabis Bioscience International Holdings, Inc. (CBIH): Investment Report

Overview

Cannabis Bioscience International Holdings, Inc. (CBIH) is a healthcare company that focuses on medical cannabis education, research, and development. As the cannabis industry continues to grow, CBIH is well-positioned to capitalize on this trend. This report provides an in-depth analysis of CBIH's financial performance, growth prospects, and recent news updates. With a market capitalization of $7.3 million, CBIH presents an attractive opportunity for investors looking to gain exposure to the cannabis sector.

Core Metrics

• Current price: $0.0007 USD
• 52-week high: $0.002 USD
• 52-week low: $0.0003 USD
• Market Cap: $7.3 million USD
• P/E Ratio: 0.07
• Earnings per Share: $0.01
• 50-day average: $0.0008156
• 200-day average: $0.000773675
• Analyst Recommendations: none (0 strong buy, 0 buy, 0 hold, 0 sell, 0 strong sell)

Financial Performance

CBIH's financial performance has been mixed over the past few years. While the company has reported revenue growth, its operating cash flow has been negative. The company's gross margins are relatively high at 76.42%, indicating that it has a solid pricing strategy in place. However, its revenue growth rate is negative, which is a concern. CBIH's total cash on hand is $794, and its free cash flow is $32,368, which is a positive sign.

Growth Prospects

CBIH's growth prospects are closely tied to the growth of the cannabis industry. As more states and countries legalize medical cannabis, the demand for CBIH's services is likely to increase. The company's focus on education and research puts it in a unique position to benefit from this trend. Additionally, CBIH's partnerships with universities and research institutions are likely to lead to new discoveries and innovations, which could further drive growth.

News and Updates

Recent news articles highlight CBIH's efforts to develop treatments for pancreatic and breast cancers, as well as its focus on education and research. The company's partnership with Johns Hopkins University is a significant development, as it provides access to cutting-edge research and technology. Additionally, CBIH's listing on the OTC market and its presence on financial websites such as Seeking Alpha and Morningstar indicate that the company is gaining visibility and traction.

Upgrades and Downgrades

There have been no upgrades or downgrades from major brokerages or analysts in recent times.

Summary

In conclusion, CBIH presents an attractive investment opportunity for those looking to gain exposure to the cannabis sector. While the company's financial performance has been mixed, its focus on education and research puts it in a strong position to benefit from the growth of the industry. With a strong gross margin and positive free cash flow, CBIH is well-positioned to capitalize on the growing demand for medical cannabis. However, investors should exercise caution due to the company's negative revenue growth rate and lack of analyst recommendations.

Disclosures

The information on this website should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on other content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Under no circumstances should any information provided on this website or social media platforms be construed as an offer soliciting the purchase or sale of any security, nor should it be construed as an offer to provide investment advisory services.